ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Schoor, J
Right arrow Articles by Pauwels, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Schoor, J
Right arrow Articles by Pauwels, R.
Eur Respir J 1998; 12: 17-23
Copyright © ERS Journals Ltd 1998

Clinical Trial

The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics

J Van Schoor, GF Joos, BL Chasson, RJ Brouard, and RA Pauwels

Inhalation of neurokinin (NK) A causes bronchoconstriction in patients with asthma. The NKA-induced bronchoconstriction in isolated human airways is mediated via the NK2 receptor and inhibited by SR 48968, a potent and specific nonpeptide tachykinin NK2 receptor antagonist. In the present study, the effect of orally administered SR 48968 on NKA-induced bronchoconstriction was examined in 12 mild asthmatics. On the screening day and during the study periods, increasing concentrations of NKA (3.3 x 10(-9) to 1.0 x 10(-6) mol x mL(-1)) were inhaled, until the forced expiratory volume in one second (FEV1) and specific airway conductance (sGaw) decreased by at least 20 and 50%, respectively. During the study periods, 100 mg SR 48968 or matched placebo was ingested in a double-blind, randomized, crossover fashion and NKA provocation was performed at 1.5 and 24 h after dosing. At 1.5 h, the mean (SEM) log10 provocative concentration of NKA causing a 20% fall in FEV1 (PC20 FEV1) was -6.25 (0.20) after SR 48968 and -6.75 (0.17) after placebo (p=0.05); the mean log10 provocative concentration of NKA causing a 35% fall in sGaw (PC35 sGaw) was -7.02 (0.28) after SR 48968 and -7.64 (0.19) after placebo (p=0.05). At 24 h, the mean log10 PC20 FEV1 was -6.21 (0.17) after SR 48968 and -6.65 (0.11) after placebo (p=0.05); the mean log10 PC35 sGaw was -6.85 (0.23) after SR 48968 and -7.17 (0.15) after placebo (nonsignificant). As PC20 FEV1 and/or PC35 sGaw were not reached in up to 4 patients per SR 48968 group, the differences between SR 48968 and placebo were underestimated. In conclusion, oral treatment with 100 mg SR 48968 caused a significant inhibition of neurokinin A-induced bronchoconstriction in asthmatics. This finding constitutes the first evidence of inhibition of sensory neuropeptide-induced bronchoconstriction by a selective tachykinin receptor antagonist in humans.


This article has been cited by other articles:


Home page
 Ther Adv Respir DisHome page
V. Schelfhout, V. Van De Velde, C. Maggi, R. Pauwels, and G. Joos
The effect of the tachykinin NK2 receptor antagonist MEN11420 (nepadutant) on neurokinin A-induced bronchoconstriction in asthmatics
Therapeutic Advances in Respiratory Disease, October 1, 2009; 3(5): 219 - 226.
[Abstract] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. D. Boot, S. de Haas, S. Tarasevych, C. Roy, L. Wang, D. Amin, J. Cohen, P. J. Sterk, B. Miller, A. Paccaly, et al.
Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma
Am. J. Respir. Crit. Care Med., March 1, 2007; 175(5): 450 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
P. E. Losco, M. W. Leach, D. Sinha, P. Davis, T. J. Schmahai, A. Nomier, T. Kakkar, L. Reyderman, and M. E. Lynch
Administration of an Antagonist of Neurokinin Receptors 1, 2, and 3 Results in Reproductive Tract Changes in Beagle Dogs, but Not Rats
Toxicol Pathol, February 1, 2007; 35(2): 310 - 322.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.J. Franklin, S.W. Turner, R.C. Mutch, and S.M. Stick
Comparison of single-breath and tidal breathing exhaled nitric oxide levels in infants
Eur. Respir. J., March 1, 2004; 23(3): 369 - 372.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G.F. Joos, W. Vincken, R. Louis, V.J. Schelfhout, J.H. Wang, M.J. Shaw, G.D. Cioppa, and R.A. Pauwels
Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients
Eur. Respir. J., January 1, 2004; 23(1): 76 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G.F. Joos and B. O'Connor
Indirect airway challenges
Eur. Respir. J., June 1, 2003; 21(6): 1050 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Van Schoor, G.F. Joos, and R.A. Pauwels
Effect of inhaled fluticasone on bronchial responsiveness to neurokinin A in asthma
Eur. Respir. J., June 1, 2002; 19(6): 997 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. L. J. Van Rensen, P. S. Hiemstra, K. F. Rabe, and P. J. Sterk
Assessment of Microvascular Leakage via Sputum Induction: The Role of Substance P and Neurokinin A in Patients with Asthma
Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1275 - 1279.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. AMADESI, J. MOREAU, M. TOGNETTO, J. SPRINGER, M. TREVISANI, E. NALINE, C. ADVENIER, A. FISHER, D. VINCI, C. MAPP, et al.
NK1 Receptor Stimulation Causes Contraction and Inositol Phosphate Increase in Medium-size Human Isolated Bronchi
Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1206 - 1211.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the European Respiratory Society.